Pfizer Inc’s experimental PFE.N COVID-19 vaccine is more than 90% effective on the basis of initial study data, the drugmaker said Monday. This is a significant milestone in the fight against the coronavirus.
Experts embraced the preliminary data from a large-scale clinical test as a landmark moment that revealed that vaccinations could help combat the pandemic. However, there would be no mass roll-out this year, and the vaccines still need regulatory approval.
- California Won’t Allow Virus Vaccines Without State Approval
- Coronavirus: Dr Anthony Fauci Warns Against Rushing Out Vaccine
Pfizer seeks U.S approval
Pfizer and BioNTech SE 22UAy. F, a German partner, confirmed they have not yet identified any significant safety issues. They also plan to obtain U.S. authorization for the vaccine’s emergency use this month. This will increase the possibility of a legislative decision as early as December. If granted, the firms predict that this year they would be able to roll out about 50 million doses. Later, in 2021, it projects to produce up to 1.3 billion doses.
‘Today is a wonderful day for science and mankind,’ said Albert Bourla, Chief Executive of Pfizer.
“In our vaccine research effort, we are hitting this important landmark at a period when the world requires it most, with outbreak rates breaking new highs, hospitals reaching over-capacity, and economies barely able to reopen,” he added.
Experts said they also needed to see complete trial data that had yet to be peer-reviewed. However, the early findings were positive.
From ear to ear, this news made me smile. Peter Horby, professor of emerging infectious diseases at the University of Oxford, reported that it is a pleasure to see some promising outcomes on this vaccine and bodes well for COVID-19 vaccines in general.
There are also several issues, such as the efficacy of the vaccination by race or age. Also, how long the vaccine can provide protection is another issue. Meanwhile, the “current standard” of social distance and face-covering will continue into the near future.
For persons aged 16 to 85, Pfizer plans to obtain U.S. emergency use authorization. To do so, two months of safety data from about half of the 44,000 participants in the research would be required. This should be available in the third week of November.
Have a tip we should know? firstname.lastname@example.org